Treatment groups | Disease stages | Mean (Pg/ml) | Std. Dev | N | Mean diff ± S.E | p-value |
Pretreatment | ESBC | 56.31 | 29.57 | 28 | 17.17 ± 14.22 | 0.230 |
| ASBC | 73.40 | 76.36 | 40 |
|
|
| ESBC | 56.31 | 29.57 | 28 | 10.40 ± 18.08 | 0.566 |
| AHMC | 45.91 | 25.74 | 21 |
|
|
| ESBC | 56.31 | 29.57 | 28 | 24.13 ± 16.24 | 0.140 |
| BBT | 80.44 | 61.03 | 21 |
|
|
| ASBC | 73.40 | 76.36 | 40 | 27.57 ± 17.07 | 0.109 |
| AHMC | 45.91 | 25.74 | 21 |
|
|
| ASBC | 73.40 | 76.36 | 40 | 6.96 ± 15.10 | 0.646 |
| BBT | 80.44 | 61.03 | 21 |
|
|
| BBT | 80.44 | 61.03 | 21 | 34.54 ± 18.78 | 0.069 |
| AHMC | 45.91 | 25.74 | 21 |
|
|
3 months Post-treatment | ESBC | 77.48 | 61.32 | 28 | 1.94 ± 18.82 | 0.918 |
ASBC | 75.54 | 110.88 | 38 |
|
| |
ESBC | 77.48 | 61.32 | 28 | 31.57 ± 23.93 | 0.190 | |
AHMC | 45.91 | 25.74 | 21 |
|
| |
ESBC | 77.48 | 61.32 | 28 | 33.64 ± 21.76 | 0.125 | |
BBT | 43.83 | 13.60 | 20 |
|
| |
ASBC | 75.54 | 110.88 | 38 | 29.63 ± 22.59 | 0.193 | |
AHMC | 45.91 | 25.74 | 21 |
|
| |
ASBC | 75.54 | 110.88 | 38 | 31.70 ± 20.27 | 0.121 | |
BBT | 43.83 | 13.60 | 20 |
|
| |
BBT | 43.83 | 13.60 | 20 | 2.07 ± 25.09 | 0.934 | |
| AHMC | 45.91 | 25.74 | 21 |
|
|
6 months Post-treatment | ESBC | 59.00 | 39.77 | 26 | 33.37 ± 14.37 | 0.023 |
ASBC | 95.58 | 72.77 | 31 |
|
| |
ESBC | 59.00 | 39.77 | 26 | 13.09 ± 17.73 | 0.463 | |
AHMC | 45.91 | 25.74 | 21 |
|
| |
ESBC | 59.00 | 39.77 | 26 |
|
| |
BBT | - | - | - |
|
| |
ASBC | 95.58 | 72.77 | 31 | 46.47 ± 16.77 | 0.007 | |
AHMC | 45.91 | 25.74 | 21 |
|
| |
ASBC | 95.58 | 72.77 | 31 |
|
| |
BBT | - | - | - |
|
| |
BBT | - | - | - |
|
| |
AHMC | 45.91 | 25.74 | 21 |
|
|